AB Sciex, Thermo Fisher Scientific Enter Separate Deals to Study Disease, Develop Workflows | GenomeWeb

This story originally ran on April 22.

AB Sciex and Thermo Fisher Scientific this week separately announced collaborations to expand research into disease areas such as cancer and develop workflows for clinical proteomics.

AB Sciex said it is working with the Samuel Lunenfeld Research Institute of Mt. Sinai Hospital in Toronto on a project that will use a new mass spectrometry platform being developed by the company. The focus of the proteomics project is to improve understanding of cancer, diabetes, and heart disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.